BrainSight AI, a cutting-edge neuroscience startup leveraging deep-tech solutions, has successfully raised $5 million in its pre-Series A funding round.
The investment round was led by IAN Alpha Fund, with additional contributions from IvyCap Ventures Advisors Private Limited, Silver Needle Ventures, and existing investors.
The funds will fuel BrainSight AI’s strategic expansion into Tier I and Tier II cities across India, alongside its efforts to secure FDA certification for entry into the US and other allied markets. The startup also plans to explore opportunities in emerging regions such as Africa and Southeast Asia. A significant portion of the capital will support the development of an innovative caregiver-focused app designed to assist families managing brain disorders, reinforcing the company’s commitment to holistic brain care.
Priyank Garg, Managing Partner at IAN Alpha Fund, expressed enthusiasm for BrainSight AI’s impactful mission. “BrainSightAI’s vision to make personalized brain care universally accessible is commendable. Their groundbreaking connectomics platform, VoxelBox, could revolutionize the diagnosis and treatment of brain disorders. We are proud to back a company that combines state-of-the-art technology with a profound social impact.”
Established in 2019 by CEO Laina Emmanuel and CTO Dr. Rimjhim Agrawal, BrainSight AI specializes in using artificial intelligence and neuroscience to address neuro-oncological and neuropsychiatric disorders. With its flagship platform, VoxelBox, the startup has pioneered advancements in brain physiology, offering transformative solutions to improve patient outcomes.
As BrainSight AI continues to push boundaries in brain health innovation, this funding marks a significant milestone in its journey to redefine brain care on a global scale
